AB 202
Alternative Names: AB-202Latest Information Update: 08 Jun 2022
At a glance
- Originator GC Lab Cell
- Developer Artiva Biotherapeutics
- Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies; NKT cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical B-cell lymphoma
Most Recent Events
- 07 Jun 2022 Preclinical trials in B-cell lymphoma in USA (Parenteral) before April 2022 (Artiva Biotherapeutics pipeline, June 2022)
- 12 Aug 2021 Artiva Biotherapeutics plans to file an IND application in 2022
- 28 Jan 2021 Artiva Biotherapeutics plans a clinical trial for B-cell lymphoma (Monotherapy, Combination therapy) in 2022 (Artiva Biotherapeutics pipeline, September 2022)